No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty

Acta Orthopaedica Scandinavica

Volumn 75, Issue 1, 2004, Pages 45-49

  Sell, Stefan ^a   Phillips, Oliver ^b   Handel, Martin ^c  

^a SANA KLINIKUM OFFENBACH   (Germany)

^b MARIENHOSPITAL STUTTGART   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; DICLOFENAC COLESTYRAMINE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HETEROTOPIC OSSIFICATION; HIP DISEASE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; TABLET FORMULATION; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; VOMITING;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; SEVERITY OF ILLNESS INDEX;

EID: 1342326820     PISSN: 00016470     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016470410001708080     Document Type: Article

References (19)

1. Ahrengart L, Lindgren U. Functional significance of heterotopic bone formation after total hip arthroplasty. J Arthroplasty 1989; 4: 125-31.
2. Ahrengart L, Blomgren G, Törnkvist H. Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 1994; 65: 139-41.
3. Brooker A F, Bowerman J W, Robinson R A, Riley L H, Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg (Am) 1973; 55: 1629-32.
4. Brune K. Optimierte Diclofenac-Therapie mit Hilfe galenischer Innovationen. In: Jahrbuch der Orthopädie (Eds Venbrocks R, Salis-Soglio G). Biermann-Verlag, Zülpich 1995: 235-41.
5. DeLee J, Ferrari A, Charnley J. Ectopic bone formation following low friction arthroplasty of the hip. Clin Orthop 1976; 129: 53-9.
6. Fingeroth RJ, Ahmed AQ. Single dose 6 Gy prophylaxis for heterotopic ossification after total hip arthroplasty. Clin Orthop 1995; 397: 131-40.
7. Fowler P D, Dawes P T, John V A, Shotton P A. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. Eur J Clin Pharmacol 1986; 31: 469-72.
8. Hanslik L, Radloff H. The pathological significance of paraarticular ossifications after total hip replacements (author's transl). Arch Orthop Unfallchir 1974; 80: 153-64.
9. Holz U, Kraner F, Weller S. Periarticular ossification following replacement of the hip joint. Clinical and radiological examination of 697 hip joints (author's transl). Z Orthop 1977; 115: 146-58.
10. Jockheck M, Willms R, Volkmann R, Sell S, Weller S, Küsswetter W. Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac. Arch Orthop Trauma Surg 1998; 117: 337-40.
11. Knelles D, Barthel T, Karrer A, Kraus U, Eulert J, Kölbl O. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg (Br) 1997; 79: 596-602.
12. Müller-Faßbender H. Diclofenac Resinat bei Patienten mit rheumatischen Beschwerden. Eine Anwendungsbeobachtung an 3839 Patienten. Fortschr Med 1998; 116: 89-94.
13. Reis H J, Küsswetter W, Schellinger T. The suppression of heterotopic ossification after total hip arthroplasty. Int Orthop 1992; 16: 140-5.
14. Ritter M A, Vaughan R B. Ectopic ossification after total hip arthroplasty. Predisposing factors, frequency, and effect on results. J Bone Joint Surg (Am) 1977; 59: 345-51.
15. Sell S, Schleh T. C-reactive protein as an early indicator of the formation of heterotopic ossifications after total hip replacement. Arch Orthop Trauma Surg 1999; 119: 205-7 .
16. The SPALA Project Team: The SPALA project - An intensive monitoring system for non-steroidal anti-inflammatory drugs. In: Adverse reactions to non-steroidal anti-inflammatory drugs (Ed. Kurowski M). Clinical Pharmacoepidemiology, Birkhäuser Verlag Basel 1992: 51-65.
17. Todd P A, Sorkin E M. Diclofenac sodium - a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244-85.
18. Wahlström O, Risto O, Djerf K, Hammerby S. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. Acta Orthop Scand 1991; 62: 419-21.
19. Yeomans N D, Tulassay Z, Juhasz L, Racz I, Howard J M, van Rensburg C J, Swannell A J, Hawkey C J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-26.